Abstract
Hibernating myocardium is commonly observed in patients with severe diffuse coronary artery disease. Vasculogenic cell-based therapy, combined with tissue engineering, is a promising revascularization solution for patients who cannot benefit from established reperfusion therapies. However, there is a lack of large animal studies evaluating the advantages of endothelial progenitor cell (EPC) transplantation in combination with biopolymers. We sought to use a clinically relevant, large animal model of myocardial hibernation to examine the benefits of EPC and polymer therapy on myocardial perfusion, metabolism, and function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
